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The proteasome is a multi-enzyme complex responsible
for orchestrating protein quality control by degrading
misfolded, damaged, abnormal and foreign proteins.
Studies related to the association of the proteasomal
system in the preservation of self-renewal in both human
and mouse pluripotent cells are sparse, and therefore a
clear indication of the emergence of a new and
important field of research. Under specific conditions the
standard proteasome switches to the newly synthesized
immunoproteasome, a catalytically active protein
chamber also involved in the regulation of protein
homeostasis, cell signaling and gene expression. Herein
we review recent data to help elucidate and highlight the
pivotal role of the proteasome complex, constitutive as
well as inducible, in the regulation of self-renewal,
pluripotency and differentiation of both embryonic and
induced pluripotent stem cells. The proteasome that is
endowed with enhanced proteolytic activity maintains
self-renewal by regulating gene expression. In addition to
protein degradation, the proteasome activator PA28,
compartments of the 19S regulatory particle and key
members of the ubiquitin pathway dictate the fate of a
pluripotent stem cell. We anticipate that our observations
will stimulate active research in this new and emerging
theme related to stem cell biology, disease and
regenerative medicine.* Correspondence: James.Adjaye@med.uni-duesseldorf.de
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The ubiquitin–proteasome system
The ubiquitin–proteasome system (UPS) is the proteolytic
machinery operative in all eukaryotes to regulate basic
cellular pathways such as cell cycle, signal transduction,
transcription, protein turnover, response to oxidative
stress and apoptosis [1,2]. Signals for post-translational
modification are induced by covalent attachment of ubi-
quitin (ubi), clearly arranged by an ATP-requiring cascade
of ubi-activating enzymes (E1; two distinct enzymes), ubi-
conjugating enzymes (E2; there are dozens) and ubi ligases
(E3; multiple E3s present) (Figure 1A) [3]. A single E1
interacts with all E2s, and distinct combinations of E2s
and E3s enable substrate specificity and regulation [3].
Mono-ubi gives rise to processes associated with signal
transduction and endocytosis, while poly-ubi marks the
degradation of the substrate(s) by the proteasome in an
ATP-dependent process (Figure 1) [4,5]. Ultimately the UPS
controls intracellular protein homeostasis and quality during
a cell’s life and death, and plays major roles in both health
and disease – for example, Alzheimer’s disease (neuro-
degenerative), transient ischemia (cardiac dysfunction) and
Sjorgen’s syndrome (autoimmune) (reviewed in [6]).
The central core of the proteasome, the 20S complex,
has a barrel-like structure composed of four rings that
consist of seven subunits (α7β7β7β7) (Figure 1B). Only
three of the seven beta subunits harbor the active
threonine site (Thr1) at the N-termini [7], serving the nu-
cleophile for proteolytic hydrolysis: the PSMB6-encoded
β1 subunits catalyze caspase-like activity; the PSMB7-
encoded β2 subunits catalyze trypsin-like activity; and the
PSMB5-encoded β5 subunits catalyze chymotrypsin-like
(Chy-L) activity (see Figure 1B, tan-colored subunits; and
Table 1) [2,8]. The 20S complex requires the 19S regula-
tory particle (RP) to degrade poly-ubi substrates and is
called the 26S (single cap) or 30S (double cap) proteasome
complex (Figure 1B) [2,9]. The 20S core complex func-
tions independently of ATP and is unable to degrade poly-
ubi substrates, unlike the 26S/30S proteasome [10].l Ltd. The licensee has exclusive rights to distribute this article, in any medium,
this time, the article is available under the terms of the Creative Commons
rg/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 The ubiquitin proteasome system. (A) ATP-dependent activation of ubiquitin (ubi) by an E1 enzyme followed by ubi conjugation
(E2) results in a high-energy E2-ubi thiol ester intermediate. The protein substrate binds via a defined recognition motif to a specific E3 ubi
ligase – multiple repetition of this cycle provokes the synthesis of a poly-ubi chain to the protein substrate, ready for the degradation by the
proteasome. For deeper insight, refer to [3]. (B) Two-dimensional diagram of the 26S and hybrid proteasome complex. Schematic presentation of
the multi-enzyme complex including the 19S regulatory particle (RP) containing lid and base, the 20S core particle with the barrel-like structure of
α7β7β7β7 and the proteasome activator complex PA28. 26S proteasome, 19S RP + 20S core; hybrid proteasome, 19S RP + 20S core + PA28. DUB,
de-ubiquitinating enzyme; PPi, pyrophosphate; Rpn, non-ATPase subunit of 19S RP; Rpt, AAA-ATPase subunit of 19S RP.
Schröter and Adjaye Stem Cell Research & Therapy Page 2 of 92014, 5:24
http://stemcellres.com/content/5/1/24The 19S RP itself is formed by the base and the lid, con-
taining 18 subunits separated into 13 non-ATPase (Rpn)
subunits and six AAA-ATPase (Rpt) subunits (Figure 1B)
[11]. The functions of the RP include: capturing the poly-
ubi proteins via PSMD4/RPN10 and ADRM1/RPN13
(lid); de-ubiquitinating these captured substrates (lid;
mainly by the de-ubiquitinating enzymes (DUBs)); and
promoting the unfolding of these substrates, completed
with the opening of the α-rings for the entry into the cen-
tral chamber (base; Rpt1 to Rpt6) [2,11,12]. The 20S core
particle can be activated by the 19S RP and also by the
proteasome activator PA28, which is a homoheptameric
complex consisting of PA28α and PA28β subunits(Figure 1B) [2]. The C-termini of PA28 intercalate into the
intersubunit pocket between adjacent α subunits and con-
trols, and also stabilize the gate opening especially during
immune response [2,13]. The contacts with inflammatory
mediators provoke the substitution of the constitutive to
the inducible catalytically active subunits, converting the
proteasome complex into the immunoproteasome (iP). The
integration of the inducible subunits PSMB9/β1i, PSMB10/
β2i and PSMB8/β5i in the 20S chamber (Figure 1B, blue-
colored subunits) alters peptidase activities, thus resulting
in a higher efficiency in the generation of selected major
histocompatibility complex class I epitopes [14-17]. The
variation of the epitopes generated by the inducible
Table 1 Overview of the specific proteasome subunits that influence the pluripotent and differentiated state
Category Systemic nomenclature HUGO Function References
19S lid Rpn6 PSMD11 Stabilize interaction between
19S RP and 20S core
[2,30,32,35,36]
Rpn11 PSMD14 De-ubiquitinating enzyme
Rpn12 PSMD8
19S base Rpt3 PSMC4 ATPase, gate-opening [2,30]






PA28 complex (PA28α) PSME1 Proteasome activator [2,13,25]
(PA28β) PSME2
Explanation of the different nomenclature of the proteasome subunits as well as their functions that are important for the pluripotent and differentiated cell fate.
HUGO, Human Genome Organization; RP, regulatory particle; Rpn, non-ATPase subunit of 19S RP; Rpt, AAA-ATPase subunit of 19S RP.
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after basic and hydrophobic residues (trypsin-like activity
and Chy-L activities), while the degradation after acidic
amino acids is reduced (caspase-like activity; see Table 1)
[18,19].
Review
The molecular signature of human embryonic stem cells
(hESCs) was first described by Sato and colleagues [20],
identifying about 900 genes including PSMB8/β5i among
the top 10. Subsequently, several studies also identified a set
of genes encoding the UPS [21-23], again further evidence
supporting the role for the proteasome machinery in the
maintenance of pluripotency. Accordingly, proteomic
analysis of three distinct hESC lines (H2, H3, H5) identified
components of the UPS, especially an enrichment of distinct
proteasomal subunits [22]. Remarkably, the subunits
that do not possess the catalytically active sites were over-
represented in these analyses [21-23]. On the contrary, un-
solved mystery exists and there are several open questions:
what is the relevance of the interplay of the different sub-
units of the multi-enzyme; is the functionality of the UPS
imparted by the catalytically active subunits; do pluripotent
stem cells need more proteasomal activity; and would inhib-
ition of the proteasome affect the maintenance and self-
renewal of pluripotent cells? Answers to some of these ques-
tions are given in the subsequent sections of this review.
The proteasome complex in murine pluripotent
stem cells
Removal of damaged proteins in pluripotent cells by the
proteasome
Evidence in support of the central role of the UPS in the
maintenance and induction of pluripotency in mouseembryonic stem cells (mESCs) and mouse somatic cells
has been provided and is reviewed by Naujokat and Saric
[24]. Interestingly, oxidatively modified proteins such as
carbonylated proteins and advanced glycation end prod-
ucts accumulate in mESCs as a consequence of reactive
oxygen species [25]. These modified proteins are enriched
in ubi conjugates [26], which naturally results in proteaso-
mal degradation.
One has to note that the protein level in the cell per se
remains unaltered, whilst the level of oxidatively dam-
aged proteins diminishes during the differentiation of
murine stem cells [13,25]. The reduction in the amount
of oxidative-modified proteins is a result of the en-
hanced activity of the 20S and not that of the ATP-
dependent 26S proteasome [25]. The de novo synthe-
sized iP is processed during transient adaption to oxida-
tive stress [27,28], thus leading to the assumption that
the inducible subunits in mESCs should be expressed in
order to mediate the cleavage of the observed damaged
proteins. On the contrary, elevated levels of Psmb8/β5i
as well as of the PA28α/PA28β subunits are detected
upon embryoid body-mediated differentiation [13].
Furthermore, no significant changes in the expression
levels of the proteasome maturation protein and a con-
stant level of both 20S core and 19S RP are observed in
pluripotent cells compared with their differentiated
counterparts [13,25]. The unaltered level of the 26S pro-
teasome complex coupled to the drastically increased
levels of the 20S complex with enhanced proteasomal
activity and also increased levels of PA28 during the
switch from a pluripotent to a somatic cell suggest that
the ATP-ubi-independent PA28–iP–PA28 complex
(double-cap PA28 on iP-20S core; Figure 2A) as well as the






PA28 - i20S - PA28 
20S inducible
B




same amount of 20S 
in NPCs and neurons
A
murine ESCs early differentiation (up to day 3)
[13, 25]
unchanged:
20S - 19S - peroxide level
upregulated in mESCs:
carbonylated proteins - AGEs
upregulated upon differentiation:
PA28 - iP - proteasome activity
Figure 2 Scheme of the distinct proteasome-types present in murine and human pluripotent and differentiated cells. (A) An abundance
of 30S proteasome is presented in mouse embryonic stem cells (mESCs) compared with 3-day differentiated ESCs. The PA28 complex is induced
upon differentiation and anchored to the inducible proteasome complex. (B) Downregulated expression of the 30S complex upon neural
progenitor cells (NPCs) and neuronal differentiation is found. In contrast to the human ESCs (hESCs), the neural cells have more free 20S complex.
AGE, advanced glycation end product; iP, immunoproteasome; RP, regulatory particle.
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ally active subunits are predominantly responsible for
the reduction in the amounts of oxidatively modified
proteins [13,25].
In murine somatic cells such as skin fibroblasts, murine
embryonic fibroblasts (MEFs) as well as liver and brain tis-
sue, the level of protein oxidation depends on degradation
by iP together with the appropriately assembled hybrid
and PA28 proteasome [27-29]. Evidence provided so far
implies that iP and PA28 play major roles in the degrad-
ation of oxidized proteins in somatic cells as well as the
process of differentiation, but not in pluripotent cells. All
in all, oxidatively damaged proteins in part govern the
steady state of pluripotency in mESCs but are mopped up
by the proteasome during the process of specified deci-
sions to exit self-renewal.
Influence of the proteasome in gene transcription on
pluripotent cells
The current view is that the proteasome is involved in
the removal of damaged proteins upon differentiation,
but is it also involved in maintaining gene regulatory
networks needed to sustain pluripotency in mESCs?Pluripotent cells have the ability to give rise to all cell
types found in the body, and this therefore assumes a
tight control of self-renewal and pluripotency. This strict
program is accompanied by a highly accessible chroma-
tin state without any influence from tissue-specific acti-
vators in mESCs [30]. Remarkably the inhibition of
proteolytic activity or the depletion of distinct proteaso-
mal subunits in mESCs results in enhanced binding of
specific transcription factors and RNA polymerase II itself,
followed by the activation of cryptic promoters, which are
epigenetically silenced and normally inactive [30]. In
contrast to the cryptic promoter, proteolysis by the 20S
proteasome at active promoters maintains transcriptional
elongation by displacing RNA polymerase II [30]. An im-
plication of this observation is that the proteasomal deg-
radation in mESCs operates at tissue-specific gene loci to
inhibit the binding of tissue-specific transcription factors
and/or RNA polymerase II, thus repressing transcription
of their target genes. This further implies that the prote-
asome acts as a transcriptional silencer in mESCs in order
to maintain pluripotency [30].
Similar to the proteolytic activity, the 19S RP regulates
gene expression by interfering with chromatin modifications.
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sembly of specific and nonspecific pre-initiation complexes,
a large complex of proteins necessary for transcription, but
only in the presence of the Psmc4/Rpt3 subunit (base) [30].
These findings would imply that the proteasome complex it-
self acts on specific regulatory regions in mESCs to prevent
aberrant transcriptional initiation that would otherwise initi-
ate the exit from pluripotency.Control of ubiquitin ligase and de-ubiquitinating enzyme
in murine pluripotent stem cells
The UPS is also involved in cell cycle control. One of the
key mechanisms underlying cell cycle control is the ubi-
mediated proteolysis of regulatory molecules (for example,
cyclin, cyclin-dependent kinases and cyclin-dependent
kinase inhibitors): two multi-protein E3 ubi ligase com-
plexes – the Skp1-cullin-F-box protein complex and the
anaphase-promoting complex – are involved in cell cycle
regulation (reviewed in [31]).
The F-box protein Fbw7/Fbxw7 influences through its
ubi ligase activity the degradation of crucial cell cycle
regulators such as c-Myc, Jun, Cyclin-E and Notch [31].
Upon binding to its specific target, umpteen cell type-
dependent networks of proteins are orchestrated by the
E3 Fbxw7 [31]. The expression of Fbxw7 is similar in
mESCs (and murine induced pluripotent stem cells
(iPSCs)) compared with MEFs [32]. Interestingly, during
the differentiation of mESCs, Fbxw7 is upregulated while
c-Myc, an essential regulator of self-renewal and pluri-
potency, is downregulated [32]. Furthermore, depletion
of Fbxw7 in mESCs induces elevated expression of
c-Myc, Oct4, Nanog and Sox2 upon early differentiation,
and reprogramming Fbxw7-silenced MEFs induces en-
hanced efficiency in the derivation of iPSCs [32].
Not only does an E3 ubi ligase regulate pluripotency,
but also a member of the lid, the DUB Psmd14/Rpn11,
seems to be a crucial factor essential for maintaining
pluripotency [32]. Psmd14/Rpn11 is expressed in mESCs
and is downregulated upon differentiation [32]. Depletion
of the lid subunit in MEFs results in the opposite effect
observed with the knockdown of Fbxw7; that is, suppres-
sion of cellular reprogramming [32]. Interestingly, the
abolition of DUB activity results in the exit of self-renewal
and pluripotency. In addition, the overexpression of
Psmd14/Rpn11 in mESCs antagonized the differentiation
and supported the pluripotent state [32]. This study once
again shows that components of the USP are essential for
cellular reprogramming and the regulation of the core
pluripotency machinery. Remarkably the proteasomal sub-
units that regulate self-renewal and pluripotency are ubi
ligase, responsible for ubi tagging, and de-ubiquitinase, re-
sponsible for the removal of ubi – this is an example of
how both sides of the coin are crucial for maintaining self-renewal and pluripotency in murine embryonic stem cells
and iPSCs.
Post-translational modifications of pluripotency-associated
transcription factors
Buckley and colleagues inhibited proteasome activity
employing MG132 (concentration and duration not speci-
fied) for the analysis of proteasome-dependent protein
turnover in mESCs and iPSCs [32]. Interestingly, Oct4,
Sox2, Nanog and c-Myc, as well as Dax1, Rex1, Dnmt3l
and Msh6, are conjugated by ubi [32,33] and thus are regu-
lated by the UPS in these cells. This is strong evidence for
the inclusion of the UPS as a pluripotency-associated regu-
lator. It is important to bear in mind that ubi-mediated
proteasomal degradation is not exclusively responsible for
post-translational modifications in mESCs. Buckley and
colleagues found an overlap of phosphorylated and ubiqui-
tinated proteins (289 in number), and demonstrated that a
considerable number are associated with pluripotency [32].
Additionally, the interplay between post-translational mod-
ifications and ubi-mediated degradation seems to be cru-
cial for maintaining self-renewal and pluripotency.
The proteasome complex in human pluripotent
stem cells
Several subunits of the lid are interacting proteins of the
DUB PSMD14/RPN11, including, for example, PSMD11/
RPN6 (Table 1). Similar to the murine DUB Psmd14/
Rpn11, the non-ATPase subunit PSMD11/RPN6 plays a
key role in human pluripotent cells [34]. Generally the lid
subunit PSMD11/RPN6 functions to stabilize the inter-
action of the 19S RP to the 20S core via the α2 subunit
[35,36]. PSMD11/RPN6 is expressed at high levels in both
embryonic stem cells and iPSCs. Differentiation of hESCs
to neural progenitor cells (NPCs) and to mature neurons
results in a downregulated expression of PSMD11/RPN6
[34]. This depletion of PSMD11/RPN6 results in reduced
proteasomal activity and consequently a reduction in the
amount of assembled proteasome complex (Figure 2B).
Downregulated expression of PSMD11/RPN6 during dif-
ferentiation is accompanied by a decrease in hydrolytic ac-
tivity of the proteasome complex. This observation is
proof that PSMD11/RPN6 is essential for preserving the
activity of the proteasome.
Analyses of the synthesized and functional proteasome
complex in hESCs compared with derived NPCs and neu-
rons revealed a higher amount of 30S proteasome
(double-cap 19S) and less 20S complex (Figure 2B). Com-
monly it seems that there is reduced proteasomal activity
in all hESC-derived cells such as trophoblasts, as well as
somatic cells such as human cortical/hippocampal astro-
cytes, fibroblasts and HEK293T [34]. In general, the UPS
plays a pivotal role in neurons, especially in synaptic trans-
mission [37], so there is no plausible explanation as to
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proteasome complexes compared with pluripotent cells.
hESCs probably also possess high levels of damaged
proteins, as demonstrated in mESCs [13,25]. Remarkably,
human pluripotent cells possess less oxidatively modified
proteins compared with human neonatal foreskin fibro-
blast (HFF)-1, embryonic stem cell-derived and iPSC-
derived fibroblast-like cells [38]; the opposite is true for
mESCs [13,25]. In addition, the authors show a higher re-
sistance of pluripotent cells to oxidative stress [38]. Add-
itionally, the increased amount of available 20S core upon
NPC and neuronal differentiation of hESCs deflects the
question of whether the PA28 complex also plays an es-
sential role in this process. Hernebring and coworkers
demonstrated that the proteasome activator is responsible
for the elevated proteolytic activity in differentiated
mESCs [13]. The possibility exists that the free 20S com-
plex, standard or inducible, can be tagged by the PA28
particle; however, this process induces an elevated level of
proteolytic activity [13,25], and therefore would suggest
the presence of the inducible proteasome complex [27,28].
Immunoproteasome in pluripotent and differentiated cells
The iP is a subtle modification of the proteasome compos-
ition and is mainly associated with antigen processing,
protein homeostasis and oxidative stress responses [28,39].
To investigate the role of iP in maintaining pluripotency,
Atkinson and colleagues observed the loss of Chy-LTable 2 Summary of proteasome inhibitors and their impact
Cell type Concentration, inhibitor/time Effect
HFF/iPSC-derived fibroblast 250, 500 and 1,000 nM
MG132/40 hours
No morpholo
Fibroblasts 2 μM UK101/PD957 Complete inh
reprogramm
MEFs Low doses of MG132 Complete inh
reprogramm
hESC-derived fibroblasts 250, 500 and 1,000 nM
MG132/40 hours
No morpholo
hESCs 125 nM MG132/40 hours No effect
250 nM MG132/40 hours Large patche
500 nM MG132/40 hours Only differen
1,000 nM MG132/40 hours Detachment








Application of distinct proteasome inhibitors on different cell types, the effect of in
hESC, human embryonic stem cell; HFF, human neonatal foreskin fibroblast; iPSC, inactivity during embryoid body-based differentiation of
hESCs [40]. This observation is in line with the decline of
the 26S activity upon differentiation in hESCs [34] and
contrary to the boost of the 26S activity upon mESCs-
derived differentiation [13,25]. The focus of this publica-
tion is on both the constitutive and inducible proteasome
complex [40].
Chy-L activity is brought about by PSMB5/β5, PSMB9/
β1i and PSMB8/β5i (Table 1) [8,14,41]. Remarkably, the
mRNA expression levels of the constitutive beta subunits
(PSMB6/β1, PSMB7/β2) were downregulated whilst the
levels of the PSMB5/β5 subunits remained unchanged
upon embryoid body-based differentiation of hESCs [40].
In contrast to the transcriptional level, the protein level of
the catalytically active constitutive subunits remained un-
altered [40]. A loss of inducible PSMB9/β1i and PSMB8/
β5i expression at both the RNA and protein levels was ob-
served after 16 days of embryoid body-mediated differen-
tiation of hESCs [40], which is further evidence in support
of the observed reduced Chy-L activity upon the loss of
pluripotency. Is it therefore possible that the observed en-
hanced proteasomal activity in pluripotent cells is detected
simply because of the iP? The studies described in [32,34]
did not investigate the role of the iP complex in maintain-
ing pluripotency. The iP itself, beyond its function of gen-
erating major histocompatibility complex class I epitopes,
has a higher protein turnover ratio [28], a shorter half-life
[17] and cleans up after inflammation [28] compared withon pluripotency
Pluripotency marker Reference







gical change Nondetectable [21]
Significant downregulation of
OCT4, SOX2, NANOG and TRA-1-60
[21]






of FGF5 and GATA4)
Significant downregulation of








hibition and the influence on pluripotency-associated transcription factors.
duced pluripotent stem cell; MEF, murine embryonic fibroblast.
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ments are warranted in order to elucidate signaling mech-
anisms beyond the (inducible) proteasomal activity during
exit of self-renewal.
Inhibition of proteasome activity affects the
induction, maintenance and exit of pluripotency
Recent microarray-based transcriptome analysis of RNAi-
based depletion of OCT4 function in the hESC H1
cell line revealed the regulation of 18 genes associated
with the proteasome pathway [23]. Altered proteasome
activity in ESCs stimulated with distinct proteasome in-
hibitors elicits different effects as summarized in Table 2.
Remarkably, inhibition of the proteasome using MG132, a
reversible and cell-permeable inhibitor, affects only pluri-
potent stem cells and not somatic cells such as HFF and
fibroblast derived from HFF-iPSCs (Table 2) [21,34,40].
Short-term treatment (~20 minutes up to 10 hours) with
high concentrations of distinct inhibitors (20 μM MG132/
8 to 10 hours [30]; 25 μM MG132, 30 μM PI-I, 10 μM lac-
tacystin/20 minutes each [34]) did not alter cell viability,
morphology or self-renewal. Interestingly, however, a low
dose of MG132 stimulation in MEFs inhibited cellular
reprogramming (Table 2) [32]. In contrast, inhibition of
proteasomal activity in pluripotent cells always led to a
downregulated expression of pluripotency-associated
genes such as OCT4, NANOG, c-MYC, SOX2, SSEA3,
TRA-1-81 and TRA-1-60, and therefore loss of self-
renewal with concomitant activated expression of differen-
tiation markers such as FGF5 and GATA4 (Table 2)
[21,34,40]. Moreover, an accumulation of the ubi-tagging
on Oct4, Nanog, c-Myc and p53 has been described [32].
The use of specific inhibitors of immunoproteasomal ac-
tivity, UK101 (PSMB9/β1i) and PK957 (PSMB8/β5i), re-
duced the efficiency of cellular reprogramming, induced
an exit of self-renewal and activated expression of somatic
markers such as FGF5 and GATA4 (Table 2) [40]. This ob-
servation is evidence that the iP complex is essential for
the induction of pluripotency in somatic cells.
Depending on the concentration of proteasome inhibi-
tor used, one can influence cell fate – high doses lead to
the exit of self-renewal [21,34,40] and inhibition of cellu-
lar reprogramming [32,40]. The entire ATP-dependent
proteolytic machinery, including the inducible complex,
seems to be a regulator of self-renewal capability.
Conclusions
The proteasome complex influences the induction,
maintenance and exit of self-renewal and pluripotency
in both mouse and human. First, together with the PA28
complex, the proteasome complex removes the high
amount of oxidatively damaged proteins upon differenti-
ation [13,25]. Second, the complex acts as a gene silen-
cer in mESCs [30]. Third, the complex regulates thepluripotency-associated cell cycle via E3 ubi ligase and
DUB [32]. Fourth, the complex modulates pluripotency
via post-translational modifications such as ubi-tagging
of the core pluripotency-associated transcription factors,
for example Oct4, Nanog and c-Myc [13,32]. Fifth, pro-
teasome inhibition induces an exit of self-renewal
[21,34,40] and the inhibition of the induction of pluripo-
tency in somatic cells [32,40]. It is now evident that the
UPS plays a pivotal role in maintaining pluripotency as
well as supporting the mopping up of damaged proteins
during differentiation.
The iP is so far accepted to fulfill almost the same
functions as the standard proteasome. These functions
include protein homeostasis, cell proliferation and differ-
entiation, transcription and major histocompatibility
complex class I signaling. To date, the functional rele-
vance of the inducible proteasome in the maintenance of
pluripotency and self-renewal in human embryonic and
induced pluripotent stem cells or in the induction of
pluripotency in somatic cells remains unexplored. Not-
ably, the inducible subunits PSMB8/β5i and PSMB9/β1i
are also expressed in human placenta [39]. Further ex-
periments are warranted to enable clarification of the
pivotal role played by this fascinating inducible multi-
enzyme protein complex in the induction, maintenance
and loss of pluripotency. The necessity for the degrading
machinery in maintaining self-renewal and pluripotent is
evident [21,34,40]. The importance of the proteolytic
machinery lies in the rapid modification of the cell cycle,
regulation of transcription and control of protein dam-
age (oxidatively and/or carbonylated) to sustain the pro-
liferation capacity of pluripotent cells.
As embryonic stem cells and iPSCs have the unique
ability to self-renew and are pluripotent, they are capable
of differentiating into cell types representative of the
three embryonic germ layers: mesoderm, endoderm and
ectoderm [42]. Murine embryonic stem cells and iPSCs
maintain pluripotency by virtue of a gene regulatory
network based on the leukemia inhibitory factor and ca-
nonical Wnt pathway [43], whereas in human this de-
pends on the fibroblast growth factor and transforming
growth factor beta/NODAL/ACTIVIN-signaling path-
ways [44,45]. It is well known that the UPS has a bearing
on these signaling pathways beside its regulatory func-
tions (leukemia inhibitory factor [46], transforming
growth factor beta [47], β-catenin/Wnt [48]). An in-
depth understanding of these signaling pathways and the
involvement of the UPS in maintaining self-renewal is
urgently needed.
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